Skip to main content
Premium Trial:

Request an Annual Quote

Lion Licenses Clones, Database to Max Planck Gesellschaft

NEW YORK, Jan 5 - Lion Bioscience said Friday it has reached an agreement to license its cDNA clone collection, arrayTAG, together with its annotation database, arrayBASE, to Germany’s Max Planck Gesellschaft’s biomedical research institutes.

Under the terms of the deal the institutes will have non-exclusive access to Lion’s first 10,000 proprietary cDNA mouse clones. Lion said that up 15 percent of these 10,000 arrayTAGs are not yet described in any public data source. The institutes will also have access to arrayBASE, a database containing information about each clone.

Financial terms were not disclosed.

The Max Planck Gesellschaft will use the expression profiling tools to produce microarrays. The integrated expression profiling system will allow researchers to identify genes associated with animal development and to study cardivascular and neurodegenerative diseases.

Based in Munich, the Max Planck Gesellschaft is a non-profit basic research institution funded by the German government.




The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.